California based SDS Ventures is launching a biotechnology fund in October 2010.
The fund is raising up to USD75m with a focus on oncology biotechnology companies with at least one phase three drug in the pipeline.
SDS Ventures has already identified a California based prospective portfolio company and is currently in the due diligence stage.
The fund is expected to close the first round of approximately USD30m by the end of 2010.
Former biotechnology chief executives and researchers have signed on to serve as the fund’s independent advisers.